Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518
Date
2021
Authors
Marathe, C.S.
Jones, K.L.
Rayner, C.K.
Wu, T.
Horowitz, M.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Diabetes Care, 2021; 44(11):e194-e195
Statement of Responsibility
Chinmay S. Marathe, Karen L. Jones, Christopher K. Rayner, Tongzhi Wu, and Michael Horowitz
Conference Name
Abstract
Abstract unavailable
School/Discipline
Dissertation Note
Provenance
Description
Comments and Responses
Access Status
Rights
© 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.